An open-label, single-dose, partially-randomized crossover third pivotal bioequivalence study of oxycodone/naltrexone (ELI 201) in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 03 Dec 2014
Price : $35 *
At a glance
- Drugs Oxycodone/naltrexone (Primary) ; Oxycodone
- Indications Pain
- Focus Pharmacokinetics; Registrational
- 03 Dec 2014 Results published in an Elite Pharmaceuticals media release.
- 03 Dec 2014 Primary endpoint has been met (bioavailability and bioequivalence of oxycodone/naltrexone controlled-release capsules to oxycodone controlled-release tablet), according to an Elite Pharmaceuticals media release.
- 26 Aug 2014 New trial record